BRTX on Nasdaq
BioRestorative Therapies, Inc.
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with MANGOCEUTICALS, INC., NewGenIvf Group Ltd or Charming Medical Ltd, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
93.4%Gross margin3
-4350.1%Operating margin3
-3959.4%Net margin3
-10.3%Revenue growth, 20253
-3992.2%Return on equity3
-$10.9MFree cash flow3
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Product brought in 83% of the revenue BioRestorative Therapies, Inc. broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2024 | 2025 |
|---|---|---|
| Product | $300.0K | $300.0K |
| Royalty | $101.0K | $59.7K |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue0¢$23.8K
- Research and development100¢$10.1M
Out of $359.7K in revenue.3 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenues | $359.7K | $401.0K |
| Cost of goods sold | $23.8K | $28.1K |
| Gross profit | $335.9K | $372.9K |
| Research and development | $10.1M | $6.7M |
| General and administrative | $5.9M | $5.2M |
| Total Operating Expenses | $16.0M | $11.9M |
| Loss From Operations | -$15.6M | -$11.6M |
| Interest income, net | $266.2K | $616.1K |
| Other income | $17.4K | $150.8K |
| Gain on exchange of warrants | $1.7M | |
| Change in fair value of warrant liabilities | $1.1M | $97.2K |
| Total Other Income | $1.4M | $2.6M |
| Net Loss | -$14.2M | -$9.0M |
| Net Loss Per Share - Basic | -$1.58 | -$1.16 |
| Net Loss Per Share - Diluted | -$1.58 | -$1.16 |
| Weighted Average Common Shares Outstanding - Basic | 9.0M shares | 7.8M shares |
| Weighted Average Common Shares Outstanding - Diluted | 9.0M shares | 7.8M shares |
Every line of the balance sheet in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $1.5M | $547.9K | |
| Investments held in marketable securities | $1.4M | $10.2M | |
| Accounts receivable | $15.5K | $188.4K | |
| Prepaid expenses and other current assets | $168.4K | $223.2K | |
| Total Current Assets | $3.1M | $11.1M | |
| Deferred offering costs | $49.8K | $148.7K | |
| Property and equipment, net | $358.8K | $362.9K | |
| Intangible assets, net | $534.2K | $623.9K | $713.7K |
| Total Assets | $4.1M | $12.3M | |
| Accounts payable | $1.3M | $483.1K | |
| Accrued expenses and other current liabilities | $982.0K | $744.5K | |
| Warrant liabilities | $1.4M | $2.5M | $1.5M |
| Total Current Liabilities | $3.7M | $3.7M | |
| Common stock, $0.0001 par value; 75,000,000 shares authorized; 8,876,242 and 6,919,919 shares issued and outstanding at December 31, 2025 and 2024, respectively | $887 | $692 | |
| Additional paid-in capital | $170.3M | $164.2M | |
| Accumulated deficit | -$169.9M | -$155.7M | |
| Total Stockholders Equity | $356.7K | $8.5M | $10.0M |
| Total Liabilities and Stockholders Equity | $4.1M | $12.3M | |
| Preferred stock, par value | $0.01 | $0.01 | |
| Preferred stock, shares authorized | 20.0M shares | 20.0M shares | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 75.0M shares | 75.0M shares | |
| Common stock, shares issued | 8.9M shares | 6.9M shares | |
| Common stock, shares outstanding | 8.9M shares | 6.9M shares |
Every line of the cash flow in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$14.2M | -$9.0M |
| Depreciation and amortization | $210.0K | $189.1K |
| Dividend and interest income | -$270.6K | -$623.8K |
| Stock-based compensation | $3.3M | $2.8M |
| Non-cash lease expense | $151.4K | |
| Gain on exchange of warrants | -$1.7M | |
| Change in fair value of warrant liabilities | -$1.1M | -$97.2K |
| Accounts receivable | $172.9K | -$169.1K |
| Prepaid expenses and other current assets | $101.8K | $33.6K |
| Accounts payable | $839.5K | $293.7K |
| Accrued expenses and other current liabilities | $195.3K | $32.8K |
| Lease Liability | -$162.3K | |
| Net Cash Used In Operating Activities | -$10.8M | -$8.2M |
| Sale of marketable securities | $11.7M | $21.5M |
| Purchase of marketable securities | -$2.7M | -$20.9M |
| Purchases of equipment | -$116.1K | -$106.2K |
| Net Cash Provided By Investing Activities | $8.9M | $514.5K |
| Proceeds from issuance of common stock for cash | $3.1M | |
| Payment of issuance costs | -$178.0K | |
| Exercise of stock options | $41.2K | |
| Proceeds from exchange and issuance of warrants, net | $7.5M | |
| Payment of deferred offering costs | -$100.0K | -$148.7K |
| Repayment of financed insurance premiums | -$4.7K | |
| Net Cash Provided By Financing Activities | $2.9M | $7.4M |
| Net Increase (Decrease) In Cash and Cash Equivalents | $963.3K | -$336.5K |
| Return and cancellation of shares in lieu of payroll tax withholding | $48.4K | |
| Issuance of common stock held in abeyance | $28 | $15 |
| Reclassification of deferred offering costs | $217.8K | |
| Deferred offering costs included in accounts payable | $18.9K | |
| Financing of insurance premiums | $47.0K |
Former names
- Stem Cell Assurance, Inc.Nov 16, 2010 to Aug 16, 20112
Recent filings
- Oct 9, 20268-K CURRENT REPORT
- Sep 11, 20268-K CURRENT REPORT
- Sep 10, 20268-K/A AMENDMENT NO. 1 TO FORM 8-K
- Sep 2, 20268-K CURRENT REPORT
- Sep 2, 20268-K CURRENT REPORT
- Aug 25, 20268-K CURRENT REPORT
- Aug 14, 20268-K
- Aug 14, 2026NT 10-Q
- Aug 3, 2026SCHEDULE 13G/A
- Jul 30, 20263
- Jul 24, 20263 PRIMARY DOCUMENT
- Jul 16, 20268-K
- Jun 18, 20263
- Jun 18, 20263
- Jun 17, 20263
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11